FDA Grants Orphan Drug Designation | 03-Mar-2025 | 12:05 | RNS |
Notice of Annual General Meeting | 28-Feb-2025 | 12:00 | RNS |
Positive EMA Opinion on Orphan Drug Designation | 27-Feb-2025 | 07:30 | RNS |
Annual Report 2024 published | 27-Feb-2025 | 07:15 | RNS |
Financial Statement 1 January to 31 December 2024 | 27-Feb-2025 | 07:00 | RNS |
Notice of Financial Statement and Annual Report | 19-Feb-2025 | 10:00 | RNS |
Holding(s) in Company | 14-Feb-2025 | 12:00 | RNS |
Change of Broker | 11-Feb-2025 | 07:30 | RNS |
Holding(s) in Company | 06-Feb-2025 | 15:00 | RNS |
Results of Oversubscribed Placing | 06-Feb-2025 | 07:00 | RNS |
Proposed Issue and Placing | 05-Feb-2025 | 16:30 | RNS |
Faron’s Financial Calendar for 2025 | 13-Dec-2024 | 07:00 | RNS |
Positive Phase 2 Interim Results from BEXMAB Trial | 27-Nov-2024 | 07:00 | RNS |
Shareholders’ Nomination Board | 05-Nov-2024 | 07:00 | RNS |
Faron’s Capital Markets Day 2024 | 22-Oct-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 205.00p |
Change Today | 5.00p |
% Change | 2.50 % |
52 Week High | 262.50p |
52 Week Low | 141.67p |
Volume | 42,442 |
Shares Issued | 116.95m |
Market Cap | £239.76m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 1 |
Buy | 3 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 1 |
Total | 6 |
No dividends found |
Time | Volume / Share Price |
15:08 | 1,000 @ 200.60p |
14:54 | 480 @ 209.00p |
14:03 | 1,001 @ 200.60p |
13:24 | 370 @ 209.00p |
10:54 | 32 @ 198.80p |
CFO | Yrjö E K Wichmann |
CEO | Juho Jalkanen |
Chair | Tuomo Pätsi |
You are here: research